Navigation

Macular oedema (diabetic) - ranibizumab (rapid review of TA237) [ID626]

Ranibizumab for the treatment of diabetic macular oedema (rapid review of TA237)

Status: History
Expected date of issue: February 2013
Referral date: July 2010
Process: STA
Notes:

Scoped within Batch 12

Topic area:
  • Endocrine, nutritional and metabolic
  • Eye
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Matthew Dyer
Communications manager: Shalu Kanal
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: 04 September 2012
2nd appraisal committee meeting 06 November 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis Pharmaceuticals (ranibizumab)

Patient/carer groups

  • Diabetes UK
  • Juvenile Diabetes Research Foundation
  • Macular Disease Society
  • Royal National Institute of Blind People (RNIB)

Professional groups

  • Royal College of Nursing
  • Royal College of Ophthalmologists
  • Royal College of Physicians

Others

  • Bridgend LHB
  • Department of Health
  • Welsh Assembly Government

General

  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • Coherent UK (photocoagulation) – did not return a confidentiality form
  • KLS Martin Group (photocoagulation) – did not return a confidentiality form
  • Litechnica (photocoagulation) – did not return a confidentiality form
  • Lumenis (UK) (photocoagulation) – did not return a confidentiality form
  • Quantel Medical (photocoagulation) – did not return a confidentiality form
  • Roche Products (bevacizumab)
  • Topcon Great Britain (photocoagulation) – did not return a confidentiality form

Relevant research groups

  • None

Evidence Review Group

  • Warwick Evidence
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Key documents

This page was last updated: 02 July 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.